<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909165</url>
  </required_header>
  <id_info>
    <org_study_id>8616-169</org_study_id>
    <secondary_id>2017-000693-11</secondary_id>
    <secondary_id>MK-8616-169</secondary_id>
    <nct_id>NCT03909165</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to &lt;2 Years (MK-8616-169)</brief_title>
  <official_title>A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to &lt;2 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics (PK) of sugammadex
      (MK-8616) for reversal of both moderate and deep neuromuscular blockade (NMB) in pediatric
      participants aged birth to &lt;2 years. The primary hypothesis of this study is that sugammadex
      is superior to neostigmine in reversing moderate NMB as measured by time to neuromuscular
      recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be conducted in two parts: Part A and Part B. In Part A, PK sampling will be
      conducted to identify the pediatric dose providing sugammadex exposure comparable to the next
      oldest age cohort. For Part B participants, the efficacy of sugammadex (i.e. neuromuscular
      recovery / time to extubation) will be assessed. Further, safety analyses will be conducted
      in both Parts A and B. Following completion of Part A, an interim analysis (IA) of the PK and
      safety data will be performed. Once the appropriate doses are confirmed and safety data is
      assessed for the 2 doses of sugammadex, then Part B will commence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">March 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part A will be open-label, while Part B will be double-blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A. Area Under the Plasma Concentration Time Curve (AUC) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The AUC for sugammadex in plasma will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Plasma Clearance (CL) of Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The CL for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Apparent Volume of Distribution (Vz) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Vz for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Apparent Volume of Distribution at Steady State (Vss) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Vss for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Maximum Plasma Concentration (Cmax) of Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Cmax for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Half-Life (t1/2) of Sugammadex in Plasma</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The t1/2 for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B. Time to Neuromuscular Recovery</measure>
    <time_frame>Within Day 1</time_frame>
    <description>Time to neuromuscular recovery will be reported, defined as the interval from administration of reversal agent to time to neuromuscular recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and B. Adverse Events (AEs)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>The number of participants experiencing an AE will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B. Time to Extubation</measure>
    <time_frame>Within Day 1</time_frame>
    <description>Time to extubation will be reported, defined as the interval from administration of reversal agent to removal of the endotracheal tube.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Part A. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) bolus of sugammadex at 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.</description>
    <arm_group_label>Part A. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_label>Part B. Sugammadex 2 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).</description>
    <arm_group_label>Part A. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_label>Part B. Sugammadex 4 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Glycopyrrolate</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.</description>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Atropine</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.</description>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1, 2,
             or 3.

          -  Has a planned non-emergent surgical procedure or clinical situation (e.g., intubation)
             that requires moderate or deep NMB with either rocuronium or vecuronium.

          -  Has a surgical procedure or clinical situation that would allow neuromuscular
             monitoring techniques to be applied for neuromuscular transmission monitoring.

          -  Is male or female, between birth and &lt;2 years of age.

        Exclusion Criteria:

          -  Is a preterm infant or neonate &lt;36 weeks gestational age at birth.

          -  Has any clinically significant condition or situation (e.g., anatomical malformation
             that complicates intubation) other than the condition requiring the use of NMBA that,
             in the opinion of the investigator, would interfere with the trial evaluations or
             optimal participation in the trial.

          -  Has a neuromuscular disorder that may affect NMB and/or trial assessments.

          -  Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency.

          -  Has or is suspected of having a family or personal history of malignant hyperthermia.

          -  Has or is suspected of having an allergy to study treatments or its/their excipients,
             to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used
             during general anesthesia.

          -  Is expected to require mechanical ventilation after the procedure.

          -  Has received or is planned to receive toremifene and/or fusidic acid via IV
             administration within 24 hours before or within 24 hours after administration of study
             treatment.

          -  Use of medication expected to interfere with study treatments given in this trial.

          -  Has been previously treated with sugammadex or has participated in a sugammadex
             clinical trial within 30 days of signing the informed consent form of this current
             trial.

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 30 days of signing the informed
             consent/assent for this current trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucille Packard Children's Hospital ( Site 3008)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-724-2320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Variety Children's Hospital D.B.A. Nicklaus Children's Hospital ( Site 3019)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-624-2853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OU Medical Center ( Site 3005)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia ( Site 3021)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>267-426-0897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh UPMC ( Site 3017)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-692-5585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGovern Medical School at UT Health/ Memorial Hermann ( Site 3014)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-498-2768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center ( Site 3013)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>802-847-2415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children s Hospital at Westmead ( Site 3805)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731766577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne ( Site 3801)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61399366086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel ( Site 3201)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3224778962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 3250)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535454525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Childrens Hospital ( Site 3750)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358504271382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 4200)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36303838557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital ( Site 3877)</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60128862863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Children Hospital Kuala Lumpur (Hospital Tunku Azizah) ( Site 3875)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>50300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60326155555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre. ( Site 3876)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379494422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center ( Site 4225)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107037379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute Complex Problems Cardiovascular Disease ( Site 4288)</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovskaya Oblast'</state>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79039082770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NMRC Obstetrics Gynecology and Perinatology n.a. V.I. Kulakov ( Site 4287)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79104716934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 4275)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031241211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children City Clinical Hospital 13 n.a N.F.Filatov ( Site 4285)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>123001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79162366627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children City Clinical Hospital #9 n.a. G.N.Speransky ( Site 4290)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>123317</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79161664094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific-Research Clinical Pediatric Institution n.a. Veltischev ( Site 4276)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79039149345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 4281)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217400620</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

